Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarkers of treatment response in bladder cancer.
Heard JR, Ahdoot M, Theodorescu D, Mitra AP. Heard JR, et al. Among authors: theodorescu d. Expert Rev Mol Diagn. 2024 Oct;24(10):957-969. doi: 10.1080/14737159.2024.2428747. Epub 2024 Nov 13. Expert Rev Mol Diagn. 2024. PMID: 39535158 Review.
Targeting Glutamine Metabolism in Prostate Cancer.
Bhowmick N, Posadas E, Ellis L, Freedland SJ, Vizio DD, Freeman MR, Theodorescu D, Figlin R, Gong J. Bhowmick N, et al. Among authors: theodorescu d. Front Biosci (Elite Ed). 2023 Jan 4;15(1):2. doi: 10.31083/j.fbe1501002. Front Biosci (Elite Ed). 2023. PMID: 36959101 Free article. Review.
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.
Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. Plimack ER, et al. Among authors: theodorescu d. Eur Urol. 2024 Oct;86(4):297-300. doi: 10.1016/j.eururo.2024.06.018. Epub 2024 Jul 14. Eur Urol. 2024. PMID: 39003201
CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.
Söhngen C, Thomas DJ, Skowron MA, Bremmer F, Eckstein M, Stefanski A, Driessen MD, Wakileh GA, Stühler K, Altevogt P, Theodorescu D, Klapdor R, Schambach A, Nettersheim D. Söhngen C, et al. Among authors: theodorescu d. FEBS J. 2023 Oct;290(20):4864-4876. doi: 10.1111/febs.16880. Epub 2023 Jun 26. FEBS J. 2023. PMID: 37254618 Free PMC article.
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr, Lerner SP. Flaig TW, et al. Among authors: theodorescu d. Eur Urol. 2023 Sep;84(3):341-347. doi: 10.1016/j.eururo.2023.06.014. Epub 2023 Jul 4. Eur Urol. 2023. PMID: 37414705 Free PMC article. Clinical Trial.
CD44 in Bladder Cancer.
Duex J, Theodorescu D. Duex J, et al. Among authors: theodorescu d. Cancers (Basel). 2024 Mar 18;16(6):1195. doi: 10.3390/cancers16061195. Cancers (Basel). 2024. PMID: 38539529 Free PMC article. Review.
349 results